Yale Cancer Center NCTN LAPS

耶鲁大学癌症中心 NCTN LAPS

• 批准号: 10582614
• 负责人: Roy S Herbst
• 金额: $ 87.91万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-08 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10582614
• 关键词: Advanced Malignant Neoplasm; Advocate; American College of Radiology Imaging Network; Award; Biology; Cancer Hospital; Cancer Patient; Caring; Chemicals; Clinical Cancer Center; Clinical Oncology; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Comprehensive Cancer Center; Connecticut; Cooperative Group Program; Detection; Diagnosis; Disease; Eastern Cooperative Oncology Group; Ensure; Epidermal Growth Factor Receptor; Faculty; Funding; Grant; Gynecologic Oncology; Hospitals; Infrastructure; International; Laboratories; Lead; Leadership; Malignant Neoplasms; Medical Oncology; Mentors; Mentorship; National Cancer Institute; Operations Research; Personnel Staffing; Phase; Physicians; Prevention approach; Program Development; Radiation Oncology; Randomized; Recording of previous events; Research; Research Personnel; Resistance; Resources; Rewards; Role; Science; Scientist; Signal Transduction; Solid; Southwest Oncology Group; Supervision; Support Groups; System; Time; Training; Translational Research; Universities; Vision; War; Work; Yale Cancer Center; cancer therapy; clinical center; drug development; hospital care; medical schools; member; next generation; patient population; performance site; pilot trial; programmed cell death protein 1; programs; santin; standard of care; success; translational potential

Project Summary Yale Cancer Center's continuing participation in the NCTN under the leadership of Dr. Charles Fuchs includes not only a solid history of strong and committed accrual to NCTN trials, but strong leadership in the trials efforts at SWOG and other groups. YCC remains committed to prioritizing NCTN trials at all the YCC clinical centers and demonstrates annual accrual beyond estimates developed in our current U10 award. For this current submission, the vision of the YCC leadership is to: 1) continue to prioritize NCTN trials for accrual and develop YCC as a major contributor to group trials with additional contribution of our Care Centers; 2) facilitate and encourage YCC faculty to assume leadership roles in SWOG and other NCTN groups by supporting their time and effort and rewarding these activities; and 3) leverage our NCTN Coordinating Committee (NCC) as a bridge to bring Yale translational science to group activities as the results of our investigator initiated pilot trials become promising for multi-center and randomized questions. In addition to the leadership efforts of Dr. Fuchs, other key SWOG leaders include Drs. Roy Herbst, Daniel Petrylak and Lajos Pusztai. Drs. Peter Glazer, Roy Decker and Alessandro Santin will lead our efforts in the NRG group in addition to Dr. Barbara Burtness who will continue to lead our efforts in the ECOG-ACRIN group. We believe that the science and translational work at YCC has strong potential for incorporation into NCTN programs. Continued work on early phase drug development, EGFR resistance, PD-1 signaling, chemical biology, and new targets in signal transduction through the scientific programs of YCC have strong potential for translation into group trials. Furthermore, with expansion of the Smilow Cancer Hospital Care Centers, we demonstrated a greater opportunity to bring NCTN trials to the greater patient population across the state of Connecticut. This UG1 grant will assist us in developing the appropriate leadership and infrastructure for support of key NCTN group efforts in both accrual and program development.

项目摘要 耶鲁癌症中心在查尔斯博士的领导下继续参加NCTN Fuchs不仅包含牢固的历史，并承诺对NCTN试验进行累计，而且还包括 在Swog和其他团体的试验中的强大领导才能。 YCC仍然致力于 优先在所有YCC临床中心进行NCTN试验的优先级，并在 在我们当前的U10奖中提出的估计值。对于当前的提交， YCC的领导力是：1）继续优先考虑NCTN试验，并将YCC作为一个 我们的护理中心的额外贡献进行小组试验的主要贡献者； 2）促进和 鼓励YCC教师在Swog和其他NCTN小组中担任领导职务 支持他们的时间和精力，并奖励这些活动； 3）利用我们的NCTN 协调委员会（NCC）是将耶鲁大学转化科学带到小组的桥梁 随着调查员的结果，活动的活动变得有希望的多中心 和随机问题。除了Fuchs博士的领导努力之外 领导者包括博士。 Roy Herbst，Daniel Petrylak和Lajos Pusztai。博士。彼得·格拉泽（Peter Glazer），罗伊（Roy） Decker和Alessandro Santin除芭芭拉博士外，还将领导我们在NRG集团的努力 Burtness将继续领导我们在Ecog-acrin集团中的努力。我们相信 YCC的科学和翻译工作具有浓厚的纳入NCTN的潜力 程序。继续研究早期药物开发，EGFR耐药性，PD-1信号传导， 化学生物学以及通过YCC的科学程序进行信号转导的新目标 具有将转化为小组试验的强大潜力。此外，随着微笑的扩展 癌症医院护理中心，我们证明了将NCTN试验带到的更多机会 康涅狄格州的患者人口越来越多。这项UG1赠款将帮助我们 开发适当的领导力和基础设施来支持NCTN集团的关键努力 在应计和计划开发中。